D-Mannose for Health & Longevity - Quick Reference Sheet

D-Mannose for Health & Longevity

Created on 07/18/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

A simple sugar that passes into the urine and blocks common infection-causing bacteria from sticking to the bladder wall. Popular for preventing repeat urinary infections without antibiotics, though the strongest study found no benefit and evidence quality is low. Safety is excellent, with mild digestive upset the main issue. Broader immune, tumor, and aging effects remain speculative. (Full Review)

Protocol

Preventive Dose
2 g/day
Powder, once daily or split; evening dosing common
Acute Dose
1.5–3 g/day
Split into 2–3 doses; adjunct, not an antibiotic replacement
Timing
Evening/bedtime
Urine retained longest overnight, maximizing contact time
Time to effect
Prevention
Weeks–months
Judged by reduced infection frequency
Acute Symptoms
1–2 days
When effective

Benefits

Contraindications
  • Fever, flank pain, or signs of upper-tract/systemic infection
  • Complicated infections, pyelonephritis, or non-E. coli organisms
Key Interactions
  • Glucose-lowering agents (insulin, sulfonylureas)
  • Diabetes
  • Advanced chronic kidney disease
  • Pregnancy or breastfeeding

Risk & Side Effects

  • High:
  • Medium: Gastrointestinal upset
  • Low: Vaginal irritation or burning; blood glucose considerations in diabetes
  • Speculative: Renal osmotic load at very high doses; unknown effects of long-term, high-dose use

Monitoring

Marker Target Why
Urine culture No significant growth; identify organism Confirms E. coli and detects resistant or non-responsive organisms
Urinalysis (leukocyte esterase, nitrites) Negative Screens for active infection and inflammation
Fasting blood glucose 70–90 mg/dL Reassurance D-mannose is not raising glucose in diabetes
HbA1c Below 5.4% Longer-term glucose control where diabetes is a concern
eGFR (with creatinine) Above 90 mL/min/1.73m² Baseline kidney function before long-term or high-dose use

Cadence: Urine culture at each suspected episode; review infection frequency at 3 and 6 months; recheck glucose and kidney function every 6–12 months in those with diabetes or kidney concerns

Qualitative Assessment

  • Frequency and severity of urinary symptoms (burning, urgency, frequency)
  • Number of infection episodes and antibiotic courses over time
  • Time between episodes (lengthening is a good sign)
  • General comfort and absence of digestive side effects at the chosen dose